(19)
(11) EP 1 425 031 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.09.2008 Bulletin 2008/36

(45) Mention of the grant of the patent:
28.05.2008 Bulletin 2008/22

(21) Application number: 02774525.6

(22) Date of filing: 20.08.2002
(51) International Patent Classification (IPC): 
A61K 38/17(2006.01)
A61P 25/00(2006.01)
A61P 9/10(2006.01)
(86) International application number:
PCT/EP2002/009294
(87) International publication number:
WO 2003/018047 (06.03.2003 Gazette 2003/10)

(54)

HDL FOR THE TREATMENT OF STROKE AND OTHER ISCHEMIC CONDITIONS

HIGH-DENSITY -LIPOPROTEIN ZUR BEHANDLUNG VON SCHLAGANFÄLLEN UND ISCHÄMIEZUSTÄNDEN

LIPOPROTEINES DE HAUTE DENSITE (HDL) POUR LE TRAITEMENT DES ACCIDENTS VASCULAIRES CEREBRAUX (AVC) ET AUTRES EVENEMENTS ISCHEMIQUES


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

(30) Priority: 20.08.2001 EP 01120026
20.08.2001 US 313605 P

(43) Date of publication of application:
09.06.2004 Bulletin 2004/24

(73) Proprietor: CSL Behring AG
3014 Bern (CH)

(72) Inventors:
  • HUBSCH, Alphonse
    3052 Münchenbuchsee (CH)
  • LANG, Markus, G.
    CH-4105 Biel-Benken (CH)
  • LERCH, Peter, G.
    CH-3007 Bern (CH)
  • PATERNO, Roberto
    I-80132 Napoli (IT)

(74) Representative: Weiss, Wolfgang et al
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München
81635 München (DE)


(56) References cited: : 
WO-A-01/03705
US-A- 5 780 592
WO-A-01/13939
   
  • COCKERILL G. W. ET AL.: "HIGH-DENSITY LIPOPROTEINS RESCUE END-STAGE ORGAN FAILURE IN A RAT MODEL OF HAEMORRHAGIC SHOCK" JOURNAL OF SUBMICROSCOPIC CYTOLOGY AND PATHOLOGY, vol. 32, no. 3, 1 July 2000 (2000-07-01), page 353 XP001073434
  • KLIMOV A N ET AL: "EFFECT OF HIGH DENSITY LIPOPROTEINS ON PERMEABILITY OF RABBIT AORTA TO LOW-DENSITY LIPOPROTEINS" ATHEROSCLEROSIS, vol. 55, no. 2, 1985, pages 217-224, XP001073581 ISSN: 0021-9150
  • OREKHOV A.N. ET AL: 'Artificial HDL as an anti-atherosclerotic drug' THE LANCET no. II, November 1984, pages 1149 - 1150
  • HAYES H.M. ET AL: 'High-Density Lipoprotein and Plaque Regression: The Good Cholesterol Gets Even Better' CIRCULATION vol. 100, 1999, pages 1762 - 1763
  • BADIMON J.J. ET AL: 'Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit' J. CLIN. INVEST. vol. 85, April 1990, pages 1234 - 1241
  • WILLIAM A.R.; THOMSON M.D.: 'BLACK'S MEDICAL DICTIONARY', 1984, ADAM & CHARLES BLACK, LONDON * page 496 - page 497 *
  • ARTHUR OSOL, PH.D.: "Blakiston's Gould Medical Dictionary, Third Edition" 1972, MCGRAW-HILL , NEW YORK * page 798 *
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).